Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Multiple Oral Doses of IX-01 in Healthy Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01994083
Recruitment Status : Completed
First Posted : November 25, 2013
Last Update Posted : September 3, 2014
Sponsor:
Information provided by (Responsible Party):
Ixchelsis Limited

Brief Summary:
The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine how the body handles IX-01.

Condition or disease Intervention/treatment Phase
Healthy Participants Drug: Placebo Drug: IX-01 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects
Study Start Date : November 2013
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Administered orally

Experimental: IX-01
Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
Drug: IX-01
Administered orally




Primary Outcome Measures :
  1. Number of Participants with One or More Drug Related Adverse Events (AEs) or any Serious AEs [ Time Frame: Baseline to Day 20 (Estimated up to 3 weeks) ]

Secondary Outcome Measures :
  1. Peak Plasma Concentration (Cmax) of IX-01 [ Time Frame: Pre-dose to 24 hours post dose on Days 1 and 10 ]
  2. Area Under the Plasma Concentration-Time Curve (AUCtau) [ Time Frame: Pre-dose up to 24 hours post dose on Days 1 and 10 ]
  3. Time of Peak Plasma Concentration (Tmax) of IX-01 [ Time Frame: Pre-dose to 24 hours post dose on Days 1 and 10 ]
  4. Elimination Half Life (t1/2) of IX-01 [ Time Frame: Pre-dose up to 96 hours post dose on Day 10 ]
  5. Accumulation Ratio (Racc) of IX-01 based on AUCtau [ Time Frame: Pre-dose up to 24 hours post dose on Day 10 ]
  6. Accumulation Ratio (Racc) of IX-01 based on Cmax [ Time Frame: Pre-dose up to 24 hours post dose on Days 1 and 10 ]
  7. Area Under the Concentration-Time Curve (AUCt) from Zero to the Time of Last Quantifiable Concentration (AUC(0-t)) of IX-01 [ Time Frame: Pre-dose to 96 hours post dose on Day 10 ]
  8. Minimum Observed Concentration (Ctrough) of IX-01 [ Time Frame: Pre-dose on Days 2 to 10 ]
  9. Elimination Rate Constant (Kel) of IX-01 [ Time Frame: Pre-dose up to 96 hours post dose on Day 10 ]
  10. Apparent Clearance of IX-01 [ Time Frame: Pre-dose up to 24 hours post dose on Day 10 ]
  11. Apparent Volume of Distribution During the Terminal Phase of IX-01 [ Time Frame: Pre-dose up to 96 hours post dose on Day 10 ]
  12. Urine 6-β-hydroxycortisol/cortisol Ratio [ Time Frame: Pre-dose on Day 1 and Day 10 ]
  13. IX-01 Concentration and Amount Secreted in Semen [ Time Frame: Between 2 and 4 hours after dosing, on Day 9 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A body mass index (Quetelet index) in the range 18-30
  • Total body weight greater than (>)50 kilograms (kg) at screening
  • Able to understand the nature of the trial and any hazards of participating in it
  • Able to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial
  • Participants and their partners must be willing to use adequate forms of contraception and comply with contraception requirements during the trial, and for 4 months after the last dose of medication
  • Must not plan to donate sperm or father a child during the trial, and for 4 months after the final dose of medication

Exclusion Criteria:

  • Clinically relevant abnormal history, physical findings, electrocardiogram (ECG), or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the participant
  • Presence of acute or chronic illness or history of chronic illness sufficient to invalidate participation in the trial or make it unnecessarily hazardous
  • Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, haematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness
  • Surgery (for example (e.g.) stomach bypass) or medical condition that might affect absorption, metabolism or elimination of medicines
  • Presence or history of severe adverse reaction to any drug
  • Use of any prescription or over-the-counter medicine during the 14 days before the first dose of trial medication, or intention to use any medicine during the trial, with the exception of short courses of medication considered by the investigator not to interfere with the safety of the participant or the integrity of the trial data (such as acetaminophen (paracetamol))
  • Current use of any herbal remedy or nutritional supplement, or intention to use any such product during the study
  • Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months
  • Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist
  • Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily
  • Blood pressure and heart rate in supine position at the screening examination outside the ranges 90-130 millimeters of mercury (mm Hg) systolic, 50-90 mm Hg diastolic; heart rate 50-90 beats/minute
  • Possibility that the participant will not cooperate with the requirements of the protocol
  • Evidence of drug abuse on urine testing
  • Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1(HIV1) or Human Immunodeficiency Virus 2 (HIV2)
  • Loss of more than 400 milliliters (mL) blood during the 3 months before the trial, e.g. as a blood donor
  • Objection by General Practitioner (GP), on medical grounds, to participant entering trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01994083


Locations
Layout table for location information
United Kingdom
Hammersmith Medicines Research (HMR)
London, United Kingdom
Sponsors and Collaborators
Ixchelsis Limited
Investigators
Layout table for investigator information
Study Director: Email: Ixchelsis@Choruspharma.com Ixchelsis Limited
Layout table for additonal information
Responsible Party: Ixchelsis Limited
ClinicalTrials.gov Identifier: NCT01994083    
Other Study ID Numbers: IX-0101
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: September 3, 2014
Last Verified: September 2014